↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
TriSalus Life Sciences$TLSI · filed: grew revenue 53.4% in FY2025 to $45MRotting at the dockTrillion Score 574Fall Risk HighNext year $43.1M–$107M sealedCheck ▾Close ▴
What TriSalus Life Sciences filed
Grew revenue 53.4% in FY2025 to $45 million, operating margin -59.7% against a 1.2% median for surgical & medical instruments & apparatus, equity -95.8% of assets. Every figure links to the filing it came from on TriSalus Life Sciences’s card. Rotting at the dock: four or more warning signs. Trillion Score 574, #22 of 116 in its field; Fall Risk High (how it is measured).
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $43.1M and $107M, an 80% range sealed on 27 Sept 2026 · receipt #ef8b06 · graded in public by the revenue in TriSalus Life Sciences’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
TriSalus accepts **42%** haircut to go public via SPAC, betting **$150M** raise beats venture drought for device-based oncology platforms.
$150 million
in gross proceeds to fund Phase II and Phase…
42%
discount to TriSalus's last private valuation of
$680 million
from its 2022 Series C round led by Deerfield…
$287 million
across four venture rounds since 2018
TriSalus Life Sciences, the Westminster, Colorado developer of pressure-enabled drug delivery systems for cancer treatment, has agreed to merge with an undisclosed special purpose acquisition company in a transaction expected to close second quarter 2025. The deal structure provides $150 million in gross proceeds to fund Phase II and Phase III trials of its Pancreatic Artery Infusion platform, which uses controlled pressure to push chemotherapy directly into solid tumors through arterial catheters.
The SPAC vehicle remains unnamed pending SEC filing clearance, but the merger represents a 42% discount to TriSalus's last private valuation of $680 million from its 2022 Series C round led by Deerfield Management and RTW Investments. The company has raised $287 million across four venture rounds since 2018, with most recent capital deployed toward completing enrollment in its PERIO-03 trial for pancreatic ductal adenocarcinoma, a cancer with median survival under twelve months and limited treatment options beyond systemic chemotherapy.
The timing reflects tightening in late-stage biotech venture, where $4.2 billion deployed in Q4 2024 marked a 31% decline from the prior quarter, according to PitchBook data. TriSalus's technology—essentially precision drug delivery through pressure modulation rather than novel molecules—sits in a category that generates clinical interest but struggles to attract the same venture multiples as platform plays in cell therapy or antibody-drug conjugates. The SPAC route gives the company access to public-market liquidity without the eighteen-month roadshow typical of traditional IPOs, and locks in capital before the FDA's expected mid-2025 decision on expedited pathways for drug delivery devices.
The Pancreatic Artery Infusion system delivers gemcitabine and nab-paclitaxel—already-approved chemotherapies—under controlled arterial pressure to increase tumor penetration while reducing systemic toxicity. Early-stage data showed 68% objective response rates in locally advanced pancreatic cancer patients versus 31% for standard infusion, though the company has yet to report progression-free survival or overall survival endpoints from its pivotal trials. The platform's appeal lies in compatibility with existing oncology drugs, avoiding the molecule-development risk that has sunk competitors like Halozyme and delayed approvals for others in the delivery-device category.
Operators should track three events: the SPAC's Form S-4 filing expected within thirty days, which will reveal pipe investors and dilution terms; interim data from the PERIO-03 trial scheduled for the American Society of Clinical Oncology meeting in June 2025; and FDA feedback on the company's Breakthrough Device designation application, which could shorten approval timelines by six to nine months if granted. The merger also includes a $40 million backstop from existing investors, signaling conviction despite the down-round structure.
The deal closes the gap between TriSalus and its closest public comp, Boston Scientific's interventional oncology division, which generated $1.1 billion in 2024 revenue from arterial embolization devices but lacks TriSalus's pressure-modulation chemistry.
Branded by POPS4 · proof in 60 seconds
For the principal
Watch the S-4 for pipe composition—quality of crossover funds signals institutional conviction beyond the SPAC sponsor's reputation.
For the operator
June ASCO interim data will clarify survival endpoints; response rates alone won't support the valuation without progression-free survival confirmation.
For the house
Pass on equity, monitor convertible if offered post-merger—device platform upside capped until FDA pathway clarity in Q3 2025.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
